Results 81 to 90 of about 1,300 (156)

Rifampicin for the treatment of a cardiogenic shock related to mavacamten toxicity: the worse and the best of drug interactions from a case report. [PDF]

Eur Heart J Case Rep
Lucas S, Hennart B, de Groote P, Lamblin N, Ridon H, Dupre C, Lionet A, Lemesle G.   +7 more
europepmc   +1 more source

Mavacamten inhibits myosin activity by stabilizing the myosin interacting-heads motif and stalling motor force generation. [PDF]

Sci Adv
McMillan SN, Pitts JRT, Barua B, Winkelmann DA, Scarff CA.   +4 more
europepmc   +1 more source

Cardiogenic shock and atrial fibrillation after mavacamten dose escalation in obstructive hypertrophic cardiomyopathy: a case report. [PDF]

Eur Heart J Case Rep
Jeong WJ, Kim SE, Cho SW, Namgung J, Ko KY.   +4 more
europepmc   +1 more source

Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
Ferraresi B, Nenna A, Jawabra M, Corrado D, Faggiano A, Carugo S, Dominici C, Casali G, Chello M, Lusini M.   +9 more
europepmc   +1 more source

Correction to: Mavacamten: First Approval

Drugs, 2022
openaire   +1 more source

Long-term clinical benefit of mavacamten for hypertrophic cardiomyopathy in a patient with <i>RAF1</i>-associated Noonan syndrome-case report. [PDF]

Eur Heart J Case Rep
Seghers HM, Ectors B, Alaerts M, Saenen J, Van Craenenbroeck EM.   +4 more
europepmc   +1 more source

Hemodynamic Implications After Left Ventricular Outflow Tract Obstruction Relief With Mavacamten. [PDF]

JACC Case Rep
Kitai T, Zhang J, Saku K.
europepmc   +1 more source

Obstructive Hypertrophic Cardiomyopathy With Degenerative Mitral Regurgitation: A New Treatment Strategy Using Mavacamten Combined With M-TEER. [PDF]

JACC Case Rep
Wang Y, Liu X, Ma L, Liu Y, Cao Y, An G, Liu F, Dong M.   +7 more
europepmc   +1 more source

Impact of Mavacamten Approval on Septal Reduction Therapy Rates in Hypertrophic Cardiomyopathy. [PDF]

J Am Heart Assoc
Ibrahim R, Wang W, Pham HN, Abdelnabi M, Lester SJ, Wilansky S, Schaff HV, Geske JB, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source

Left ventricular flow components and myocardial deformation following treatment for hypertrophic obstructive cardiomyopathy: a retrospective cardiac magnetic resonance-based cohort of mavacamten <i>vs.</i> septal myectomy. [PDF]

Cardiovasc Diagn Ther
Chen Y, Luo X, Yang Y, Ou J, Liu H.
europepmc   +1 more source